Use of recombinant activated factor VII (Novoseven) in trauma and surgery: Analysis of outcomes reported to an international registry

Journal of Intensive Care Medicine

Volumn 21, Issue 1, 2006, Pages 27-39

  Grounds, R Michael ^a   Seebach, Caroline ^b   Knothe, Christoph ^c   Paluszkiewicz, Piotr ^d   Smith, Terry S ^e   Kasal, Eduard ^f   Lecumberri, Ramon ^g   Urbanec, Rene ^h   Haas, Thorsten ⁱ   Wujtewicz, Maria ^j   Rehorkova, Dagmar ^k   Pelichovska, Martina ^l   Lange, Martina ^m   Uranga, Maite ⁿ   Bosman, Roman ^o   Rommes, J Hans ⁱ   Koscielny, Juergen ^p  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b GOETHE UNIVERSITY   (Germany)

^c Klinikum Rosenheim   (Germany)

^d MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f CHARLES UNIVERSITY   (Czech Republic)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

^h UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

ⁱ Department of Anaesthesiology and Critical Care Medicine ^*  (Netherlands)

^j MEDICAL UNIVERSITY OF GDANSK   (Poland)

^k Traumatological Hospital of Brno   (Czech Republic)

^l UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^m R Elle Hospitasl   (Germany)

ⁿ HOSPITAL DONOSTIA   (Spain)

^o Charles Teaching Hospital   (Czech Republic)

^p CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

Bleeding; Hemostasis; NovoSeven; Recombinant activated factor VII; Surgery; Trauma

Indexed keywords

APROTININ; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG USE; DYSPNEA; ERYTHROCYTE CONCENTRATE; FEMALE; GANGRENE; HEART INFARCTION; HEMORRHAGIC SHOCK; HEMOSTASIS; HUMAN; HYPOTENSION; INJURY; LIVER FAILURE; MALE; MESENTERY DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; MULTIPLE ORGAN FAILURE; NECROTIZING COLITIS; OUTCOME ASSESSMENT; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; QUADRIPLEGIA; REGISTER; SCORING SYSTEM; SEPTIC SHOCK; STAPHYLOCOCCUS INFECTION; SURGICAL PATIENT; TACHYCARDIA; TRAUMATOLOGY; UNSPECIFIED SIDE EFFECT; WOUND INFECTION;

ADOLESCENT; ADULT; AGED; BLOOD LOSS, SURGICAL; CANADA; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; FACTOR VIIA; FEMALE; HEMORRHAGE; HEMOSTATIC TECHNIQUES; HUMANS; INJURY SEVERITY SCORE; MALE; MIDDLE AGED; REGISTRIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WOUNDS AND INJURIES;

EID: 33644974322     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066605285024     Document Type: Article

References (35)

1. Ferrara A, MacArthur JD, Wright HK, Modlin IM, McMillen MA. Hypothermia and acidosis worsen coagulopathy in the patient requiring massive transfusion. Am J Surg. 1990;160:515-518.
2. Williamson LM, Lowe S, Love EM, et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. BMJ. 1999;319:16-19.
3. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma. 2001;51:431-439.
4. Claridge JA, Sawyer RG, Schulman AM, McLemore EC, Young JS. Blood transfusions correlate with infections in trauma patients in a dose-dependent manner. Am Surg. 2002;68:566-572.
5. Hill GE, Frawley WH, Griffith KE, Forestner JE, Minei JP. Allogeneic blood transfusion increases the risk of post-operative bacterial infection: a meta-analysis. J Trauma. 2003;54:908-914.
6. Sawyer PR, Harrison CR. Massive transfusion in adults. Diagnoses, survival and blood bank support. Vox Sang. 1990;58:199-203.
7. Harvey MP, Greenfield TP, Sugrue ME, Rosenfeld D. Massive blood transfusion in a tertiary referral hospital. Clinical outcomes and haemostatic complications. Med J Aust. 1995;163:356-359.
8. Davies MJ, Allen A, Kort H, et al. Prospective, randomized, double-blind study of high-dose aprotinin in pediatric cardiac operations. Ann Thorac Surg. 1997;63:497-503.
9. Llamas P, Cabrera R, Gomez-Arnau J, Fernandez MN. Hemostasis and blood requirements in orthotopic liver transplantation with and without high-dose aprotinin. Haematologica. 1998;83:338-346.
10. Dunn CJ, Goa KL. Fibrin sealant: a review of its use in surgery and endoscopy. Drugs. 1999;58:863-886.
11. Carless PA, Anthony DM, Henry DA. Systematic review of the use of fibrin sealant to minimize perioperative allogeneic blood transfusion. Br J Surg. 2002;89:695-703.
12. Flati G, Andren-Sandberg A, La Pinta M, Porowska B, Carboni M. Potentially fatal bleeding in acute pancreatitis: pathophysiology, prevention, and treatment. Pancreas. 2003;26:8-14.
13. Hedner U. NovoSeven as a universal haemostatic agent. Blood Coagul Fibrinolysis. 2000:11(suppl 1):S107-S111.
14. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet. 2003;361:201-205.
15. Lodge JP, Jonas S, Oussoultzoglou E, et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology. 2005;102:269-275.
16. Lodge JPA, Jonas S, Jones RM, et al. Efficacy and safety of repeated peri-operative doses of recombinant factor VIIa in liver transplantation. Liver Transplant. 2005;11:973-979.
17. Raobaikady R, Redman J, Ball JA, Maloney G, Grounds RM. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. Br J Anaesth. 2005;94:586-591.
18. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel, randomized placebo-controlled, double-blind clinical trials. J Trauma. 2005;59:8-18.
19. Baker SP, O'Neill B, Haddon W Jr, Long WB. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma. 1974;14:187-196.
20. Boyd CR, Tolson MA, Copes WS. Evaluating trauma care: the TRISS method. Trauma Score and the Injury Severity Score. J Trauma. 1987;27:370-378.
21. Champion HR, Sacco WJ, Copes WS, et al. A revision of the Trauma Score. J Trauma. 1989;29:623-629.
22. Champion HR, Sacco WJ, Copes WS. Injury severity scoring again. J Trauma. 1995;38:94-95.
23. Copeland GP, Jones D, Walters M. POSSUM: a scoring system for surgical audit. Br J Surg. 1991;78:355-360.
24. Prytherch DR, Whiteley MS, Higgins B, et al. POSSUM and Portsmouth POSSUM for predicting mortality. Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity. Br J Surg. 1998;85:1217-1220.
25. Hoffman M, Monroe DM III, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis. 1998;9(suppl 1):S61-S65.
26. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:542-547.
27. White B, McHale J, Ravi N. Successful use of recombinant FVIIa in the management of post-surgical intra-abdominal haemorrhage. Br J Haematol. 1999;107:677-78.
28. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999;354:1879.
29. Kristensen J, Killander A, Hippe E, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis. 1996;26(suppl 1):159-164.
30. Clark AD, Gordon WC, Walker ID, Tait RC. "Last-ditch"' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang. 2004;86:120-124.
31. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology. 2004;127:1123-1130.
32. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-785.
33. Bernstein D, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIA corrects prothombin time in cirrhotic patients: a preliminary study. Gastroenterology. 1997;113:1930-1937.
34. Ejlersen E, Melsen T, Ingerslev J, Andresen R, Vilstrup H. Recombinant activated factor VIIa (rFVIIa) acutly normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol. 2001;36:1081-1085.
35. McIlroy B, Millar A, Copeland GP, Kiff R. Audit of emergency preoperative resuscitation. Br J Surg. 1994;81:200-202.